<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176591</url>
  </required_header>
  <id_info>
    <org_study_id>811184</org_study_id>
    <secondary_id>K01DA025073</secondary_id>
    <nct_id>NCT01176591</nct_id>
  </id_info>
  <brief_title>HBPL Study of the Impact of the NK1 Antagonist Aprepitant</brief_title>
  <official_title>Human Behavioral Pharmacology Laboratory (HBPL) Study of the Impact of the NK1 Antagonist Aprepitant (EmendÂ®) on Stress-Induced Cocaine and Alcohol Craving</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed research will focus on investigating the determinants and consequences of CAD
      via measurement of physiological, behavioral and subjective effects of physiologic and
      psychologic stress cues in CAD volunteers in the laboratory, and through examination of the
      effects of the effects of Aprepitant, an NK1 antagonist, on the above effects. This study
      will examine the effects of the above stress cues on cocaine and alcohol craving under acute
      Aprepitant dosing, and under placebo conditions. The study is a within-subjects crossover
      design using 24 subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non treatment seeking subjects with DSM IV cocaine and alcohol dependence were included.
      Subjects received double-blind acute dosing of 80 mg of aprepitant (Emend) at session start,
      or matched placebo. During each session subjects were exposed to one of two types of
      stressors, one stressor per session, presented in counterbalanced order across participants.
      The Physiologic stress was the cold-pressor task. Subjects immersed their hand in cold water
      for up to 3 minutes. The psychological stress was the Trier Social Stress Test it was
      completed in 25 minutes: 5 min audio taped instructions, 10 min to mentally prepare for their
      performance tasks, 5 min to complete a public speaking task and 5 min to complete a mental
      arithmetic task. Outcome measures included: Alcohol Craving measured by visual analog scale,
      cocaine craving measured by visual analog scale and The Multiple Choice Procedure. Each
      assessment was done during study screening, and then at multiple times during each study
      session.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Craving as Measured on the Visual Analog Scale (VAS) 1</measure>
    <time_frame>Session 1</time_frame>
    <description>The VAS is a 100 mm line anchored at both ends. Participants mark where on the line their craving falls, with closer to 0 indicating less craving, and closer to 100 indicating more craving. Data are analyzed by using a ruler to determine the actual mm value of the participant mark.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol Craving as Measured by the Visual Analog Scale (VAS) 1</measure>
    <time_frame>Session 1</time_frame>
    <description>The VAS is a 100 mm line anchored at both ends. Participants mark where on the line their craving falls, with closer to 0 indicating less craving, and closer to 100 indicating more craving. Data are analyzed by using a ruler to determine the actual mm value of the participant mark.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cocaine Craving as Measured on the Visual Analog Scale (VAS) 2</measure>
    <time_frame>Session 2</time_frame>
    <description>The VAS is a 100 mm line anchored at both ends. Participants mark where on the line their craving falls, with closer to 0 indicating less craving, and closer to 100 indicating more craving. Data are analyzed by using a ruler to determine the actual mm value of the participant mark.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol Craving as Measured by the Visual Analog Scale (VAS) 2</measure>
    <time_frame>Session 2</time_frame>
    <description>The VAS is a 100 mm line anchored at both ends. Participants mark where on the line their craving falls, with closer to 0 indicating less craving, and closer to 100 indicating more craving. Data are analyzed by using a ruler to determine the actual mm value of the participant mark.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiple Choice Procedure (MCP) 1</measure>
    <time_frame>Session 1</time_frame>
    <description>The MCP measures the relative reinforcing value of a hypothetical single dose of cocaine, as compared to various monetary values. The lower the monetary value where participants switch from preferring cocaine to preferring money, the less value they place on cocaine. MCP findings of cocaine devaluation typically correlate with cocaine abstinence in clinical trials.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Choice Procedure (MCP) 2</measure>
    <time_frame>Session 2</time_frame>
    <description>The MCP measures the relative reinforcing value of a hypothetical single dose of cocaine, as compared to various monetary values. The lower the monetary value where participants switch from preferring cocaine to preferring money, the less value they place on cocaine. MCP findings of cocaine devaluation typically correlate with cocaine abstinence in clinical trials.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Cocaine Dependence</condition>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo Session 1, Aprepitant Session 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive placebo in session 1 and Aprepitant in session 2 of a psychological stressor presentation and receive placebo in session 1 and Aprepitant in session 2 of a physiological stressor presentation. Participants take Aprepitant (80 mg) or placebo tablets for 7 days prior to each session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Session 1, Placebo Session 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo in session 1 and placebo in session 2 of a psychological stressor presentation and receive placebo in session 1 and placebo in session 2 of a physiological stressor presentation. Participants take placebo tablets for 7 days prior to each session. The placebo group is used for analysis purposes in order to control for any order effects found in the Experimental group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo session 1, Aprepitant session 2</intervention_name>
    <description>placebo in session 1, Aprepitant 80 mg in session 2, oral administration.</description>
    <arm_group_label>Placebo Session 1, Aprepitant Session 2</arm_group_label>
    <other_name>Aprepitant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo session 1, Placebo session 2</intervention_name>
    <description>Placebo, one per session, oral administration</description>
    <arm_group_label>Placebo Session 1, Placebo Session 2</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Male or female and 18 years of age to 60

          2. The subject has used cocaine and alcohol at least once per month for at least the past
             year, and has used cocaine and alcohol within 30 days prior to signing consent.

          3. Live within a commutable distance of the Treatment Research Center (TRC) at the
             Penn/VA Center for Studies of Addiction, University of Pennsylvania. We define this to
             be a distance within the service area of Septa, within an hour drive, or a distance
             that both the patient and Principal Investigator (PI) find acceptable.

          4. Understands and signs the informed consent.

        Exclusion Criteria:

          1. Meets Diagnostic and Statistical Manual of Mental Disorders (DSM IV) criteria for
             current dependence on any substance other than nicotine, cocaine ,alcohol or marijuana

          2. Subjects who test positive on the urine drug screen for any illicit drugs other than
             cocaine and marijuana during screening will be allowed a single retest. Those
             individuals who test positive for amphetamine during screening, given that they
             provide a copy of a prescription, will only be included if they can safely discontinue
             amphetamine use for the duration of the study. Subjects will need to provide a urine
             free of all illicit drugs other than cocaine and marijuana at study onset to be
             randomized. Subjects who test positive for any drugs other than marijuana prior to a
             study session will be allowed a single retest and a chance to reschedule their
             session. If the subject tests positive for any drug other than marijuana at the
             retest, their participation in the study will be terminated.

          3. Subjects who meet current or lifetime DSM-IV criteria for bipolar affective disorder,
             schizophrenia, or any psychotic disorder

          4. Current severe psychiatric symptoms- (e.g., psychosis, dementia, suicidal or homicidal
             ideation, mania or depression requiring anti-depressant therapy) as diagnosed using
             the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID), the Hamilton
             Anxiety Rating Scale (Ham A), and Hamilton Rating Scale for Depression (HAM-D).

          5. Individuals scoring &gt; 10 on the Hamilton Rating Scale for Depression (HAM-D).

          6. Use of any investigational medication within the past 30 days.

          7. Concomitant treatment with psychotropic medications or prescription opioids.

          8. Concomitant use of any one of the following drugs or classes of drugs:

             Reserpine Verapamil theophylline, trimethoprim, cimetidine, haloperidol,
             benzodiazepines, or antiepileptic drugs (AEDs).

          9. Patients with a known hypersensitivity to aprepitant.

         10. Patients with severe concurrent illnesses such as bronchospastic disease,
             hyperthyroidism, diabetes mellitus.

         11. Patients with known AIDS or other serious illnesses that may require hospitalization
             during the study.

         12. Female subjects who are pregnant or lactating, or female subjects of child-bearing
             potential who are not using acceptable methods of birth control; acceptable methods of
             birth control include:

             Barrier method (diaphragm or condom) with spermicide Intrauterine progesterone
             contraceptive system Levonorgestrel implant Medroxyprogesterone acetate contraceptive
             injection, or Oral contraceptives.

         13. Patients with impaired renal function, as indicated by corrected creatinine clearance
             below 60 ml/min as determined by the modified Cockcroft equation (CDC, 1986).

         14. An unacceptable liver panel or liver function tests (LFTs) that may be indicative of
             hepatic dysfunction.

         15. Clinical laboratory tests (e.g., complete blood count (CBC), blood chemistries,
             urinalysis) outside normal limits, as determined by the study PI.

         16. History of significant heart disease or dysfunction (e.g., an arrhythmia which
             required medication, Wolff Parkinson -White Syndrome, angina pectoris, documented
             history of myocardial infarction, heart failure).

         17. Electrocardiography (EKG) indicative of 1st degree heart block, sinus tachycardia,
             left-axis deviation, non-specific ST or T-wave changes.

         18. History of chest pain associated with cocaine use that prompted a visit to a
             physician.

         19. Any medical or psychological condition that could jeopardize the subject's safe
             participation in the trial as determined by the PI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyle M Kampman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Perelman School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania, Treatment Research Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2010</study_first_posted>
  <results_first_submitted>March 18, 2015</results_first_submitted>
  <results_first_submitted_qc>July 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2020</results_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cocaine and alcohol dependence (CAD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Session 1, Aprepitant Session 2</title>
          <description>Placebo in session 1; Aprepitant: 80 mg in session 2, oral administration.</description>
        </group>
        <group group_id="P2">
          <title>Placebo in Session 1, Placebo in Session 2</title>
          <description>Placebo, one per session, oral administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Session 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Session 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Session 1, Aprepitant Session 2</title>
          <description>Placebo in session 1; Aprepitant: 80 mg in session 2, oral administration.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Session1, Placebo Session 2</title>
          <description>Placebo, one per session, oral administration</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Craving as Measured on the Visual Analog Scale (VAS) 1</title>
        <description>The VAS is a 100 mm line anchored at both ends. Participants mark where on the line their craving falls, with closer to 0 indicating less craving, and closer to 100 indicating more craving. Data are analyzed by using a ruler to determine the actual mm value of the participant mark.</description>
        <time_frame>Session 1</time_frame>
        <population>Comparing Placebo to Placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Session 1, Aprepitant Session 2</title>
            <description>Placebo in session 1; Aprepitant: 80 mg in session 2, oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Session 1, Placebo Session 2</title>
            <description>Placebo in Session 1, Placebo in Session 2, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Craving as Measured on the Visual Analog Scale (VAS) 1</title>
          <description>The VAS is a 100 mm line anchored at both ends. Participants mark where on the line their craving falls, with closer to 0 indicating less craving, and closer to 100 indicating more craving. Data are analyzed by using a ruler to determine the actual mm value of the participant mark.</description>
          <population>Comparing Placebo to Placebo</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="0" upper_limit="95"/>
                    <measurement group_id="O2" value="48" lower_limit="1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Alcohol Craving as Measured by the Visual Analog Scale (VAS) 1</title>
        <description>The VAS is a 100 mm line anchored at both ends. Participants mark where on the line their craving falls, with closer to 0 indicating less craving, and closer to 100 indicating more craving. Data are analyzed by using a ruler to determine the actual mm value of the participant mark.</description>
        <time_frame>Session 1</time_frame>
        <population>Comparing Placebo to Placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Session 1, Aprepitant Session 2</title>
            <description>Placebo session 1, Aprepitant 80 mg session 2, oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Session 1, Placebo Session 2</title>
            <description>Placebo, one per session, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Craving as Measured by the Visual Analog Scale (VAS) 1</title>
          <description>The VAS is a 100 mm line anchored at both ends. Participants mark where on the line their craving falls, with closer to 0 indicating less craving, and closer to 100 indicating more craving. Data are analyzed by using a ruler to determine the actual mm value of the participant mark.</description>
          <population>Comparing Placebo to Placebo</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.25" lower_limit="0" upper_limit="94"/>
                    <measurement group_id="O2" value="38.92" lower_limit="2" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Craving as Measured on the Visual Analog Scale (VAS) 2</title>
        <description>The VAS is a 100 mm line anchored at both ends. Participants mark where on the line their craving falls, with closer to 0 indicating less craving, and closer to 100 indicating more craving. Data are analyzed by using a ruler to determine the actual mm value of the participant mark.</description>
        <time_frame>Session 2</time_frame>
        <population>Comparing Aprepitant to Placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Session 1, Aprepitant Session 2</title>
            <description>Placebo in session 1; Aprepitant: 80 mg in session 2, oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Session 1, Placebo Session 2</title>
            <description>Placebo in Session 1, Placebo in Session 2, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Craving as Measured on the Visual Analog Scale (VAS) 2</title>
          <description>The VAS is a 100 mm line anchored at both ends. Participants mark where on the line their craving falls, with closer to 0 indicating less craving, and closer to 100 indicating more craving. Data are analyzed by using a ruler to determine the actual mm value of the participant mark.</description>
          <population>Comparing Aprepitant to Placebo</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="0" upper_limit="84"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.046</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Alcohol Craving as Measured by the Visual Analog Scale (VAS) 2</title>
        <description>The VAS is a 100 mm line anchored at both ends. Participants mark where on the line their craving falls, with closer to 0 indicating less craving, and closer to 100 indicating more craving. Data are analyzed by using a ruler to determine the actual mm value of the participant mark.</description>
        <time_frame>Session 2</time_frame>
        <population>Comparing Aprepitant to Placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Session 1, Aprepitant Session 2</title>
            <description>Placebo session 1, Aprepitant 80 mg session 2, oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Session 1, Placebo Session 2</title>
            <description>Placebo, one per session, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Alcohol Craving as Measured by the Visual Analog Scale (VAS) 2</title>
          <description>The VAS is a 100 mm line anchored at both ends. Participants mark where on the line their craving falls, with closer to 0 indicating less craving, and closer to 100 indicating more craving. Data are analyzed by using a ruler to determine the actual mm value of the participant mark.</description>
          <population>Comparing Aprepitant to Placebo</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.22" lower_limit="0" upper_limit="84"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Choice Procedure (MCP) 1</title>
        <description>The MCP measures the relative reinforcing value of a hypothetical single dose of cocaine, as compared to various monetary values. The lower the monetary value where participants switch from preferring cocaine to preferring money, the less value they place on cocaine. MCP findings of cocaine devaluation typically correlate with cocaine abstinence in clinical trials.</description>
        <time_frame>Session 1</time_frame>
        <population>Comparing Placebo to Placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Session 1, Aprepitant Session 2</title>
            <description>Placebo session 1, Aprepitant 80 mg session 2, oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Session 1, Placebo Session 2</title>
            <description>Placebo, one per session, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Choice Procedure (MCP) 1</title>
          <description>The MCP measures the relative reinforcing value of a hypothetical single dose of cocaine, as compared to various monetary values. The lower the monetary value where participants switch from preferring cocaine to preferring money, the less value they place on cocaine. MCP findings of cocaine devaluation typically correlate with cocaine abstinence in clinical trials.</description>
          <population>Comparing Placebo to Placebo</population>
          <units>dollars</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.58" lower_limit="0.75" upper_limit="20"/>
                    <measurement group_id="O2" value="17.33" lower_limit="12" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Choice Procedure (MCP) 2</title>
        <description>The MCP measures the relative reinforcing value of a hypothetical single dose of cocaine, as compared to various monetary values. The lower the monetary value where participants switch from preferring cocaine to preferring money, the less value they place on cocaine. MCP findings of cocaine devaluation typically correlate with cocaine abstinence in clinical trials.</description>
        <time_frame>Session 2</time_frame>
        <population>Comparing Aprepitant to Placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Session 1, Aprepitant Session 2</title>
            <description>Placebo session 1, Aprepitant 80 mg session 2, oral administration.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Session 1, Placebo Session 2</title>
            <description>Placebo, one per session, oral administration</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Choice Procedure (MCP) 2</title>
          <description>The MCP measures the relative reinforcing value of a hypothetical single dose of cocaine, as compared to various monetary values. The lower the monetary value where participants switch from preferring cocaine to preferring money, the less value they place on cocaine. MCP findings of cocaine devaluation typically correlate with cocaine abstinence in clinical trials.</description>
          <population>Comparing Aprepitant to Placebo</population>
          <units>dollars</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.59" lower_limit="0.75" upper_limit="16"/>
                    <measurement group_id="O2" value="17.33" lower_limit="12" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks</time_frame>
      <desc>Participants reported adverse events to nurse at each study visit, based on a list of known adverse events and novel adverse events were also recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Session1, Aprepitant Session 2</title>
          <description>Placebo in session 1; Aprepitant: 80 mg in session 2, oral administration</description>
        </group>
        <group group_id="E2">
          <title>Placebo Session1, Placebo Session 2</title>
          <description>Placebo, one per session, oral administration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jennifer Plebani</name_or_title>
      <organization>UPenn</organization>
      <phone>215-222-3200 ext 152</phone>
      <email>jplebani@upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

